FR2918566B1 - Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine. - Google Patents

Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.

Info

Publication number
FR2918566B1
FR2918566B1 FR0756421A FR0756421A FR2918566B1 FR 2918566 B1 FR2918566 B1 FR 2918566B1 FR 0756421 A FR0756421 A FR 0756421A FR 0756421 A FR0756421 A FR 0756421A FR 2918566 B1 FR2918566 B1 FR 2918566B1
Authority
FR
France
Prior art keywords
vinflunine
pharmaceutical composition
water soluble
soluble salt
stable pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0756421A
Other languages
English (en)
Other versions
FR2918566A1 (fr
Inventor
Bruno Paillard
Jean Louis Avan
Joel Bougaret
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR0756421A priority Critical patent/FR2918566B1/fr
Priority to TW097125680A priority patent/TW200914018A/zh
Priority to RU2010103934/15A priority patent/RU2462248C2/ru
Priority to BRPI0814216A priority patent/BRPI0814216A2/pt
Priority to EP08786000A priority patent/EP2187886A1/fr
Priority to AU2008274223A priority patent/AU2008274223A1/en
Priority to US12/668,367 priority patent/US9173842B2/en
Priority to SA08290417A priority patent/SA08290417B1/ar
Priority to KR1020107001420A priority patent/KR20100047230A/ko
Priority to PA20088789101A priority patent/PA8789101A1/es
Priority to NZ583040A priority patent/NZ583040A/en
Priority to PCT/EP2008/058893 priority patent/WO2009007388A1/fr
Priority to JP2010515500A priority patent/JP2010533139A/ja
Priority to CN2008800239960A priority patent/CN101730533B/zh
Priority to CA2695039A priority patent/CA2695039A1/fr
Priority to ARP080102967A priority patent/AR067499A1/es
Publication of FR2918566A1 publication Critical patent/FR2918566A1/fr
Application granted granted Critical
Publication of FR2918566B1 publication Critical patent/FR2918566B1/fr
Priority to TNP2010000013A priority patent/TN2010000013A1/fr
Priority to ZA201000335A priority patent/ZA201000335B/xx
Priority to MA32552A priority patent/MA32045B1/fr
Priority to CO10011475A priority patent/CO6160316A2/es
Priority to CL2008002005A priority patent/CL2008002005A1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0756421A 2007-07-11 2007-07-11 Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine. Expired - Fee Related FR2918566B1 (fr)

Priority Applications (21)

Application Number Priority Date Filing Date Title
FR0756421A FR2918566B1 (fr) 2007-07-11 2007-07-11 Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
TW097125680A TW200914018A (en) 2007-07-11 2008-07-08 Stable pharmaceutical composition comprising a hydrosoluble vinflunine salt
CN2008800239960A CN101730533B (zh) 2007-07-11 2008-07-09 包含水溶性长春氟宁盐的稳定的药物组合物
EP08786000A EP2187886A1 (fr) 2007-07-11 2008-07-09 Composition pharmaceutique stable comprenant un sel de vinflunine hydrosoluble
AU2008274223A AU2008274223A1 (en) 2007-07-11 2008-07-09 Stable pharmaceutical composition comprising a hydrosoluble vinflunine salt
US12/668,367 US9173842B2 (en) 2007-07-11 2008-07-09 Stable pharmaceutical composition comprising a hydrosoluble vinflunine salt
SA08290417A SA08290417B1 (ar) 2007-07-11 2008-07-09 تركيبة دوائية ثابتة تشمل ملح فينفلونين القابل للذوبان فى الماء
KR1020107001420A KR20100047230A (ko) 2007-07-11 2008-07-09 수용성 빈플루닌 염의 안정적인 약학적 조성물
PA20088789101A PA8789101A1 (es) 2007-07-11 2008-07-09 Composición farmacéutica estable que comprende una sal de vinflunina hidrosoluble
NZ583040A NZ583040A (en) 2007-07-11 2008-07-09 Stable pharmaceutical composition comprising a hydrosoluble vinflunine
RU2010103934/15A RU2462248C2 (ru) 2007-07-11 2008-07-09 Стабильная фармацевтическая композиция, содержащая водорастворимую соль винфлунина
JP2010515500A JP2010533139A (ja) 2007-07-11 2008-07-09 水溶性ビンフルニン塩を含んでなる安定な医薬組成物
BRPI0814216A BRPI0814216A2 (pt) 2007-07-11 2008-07-09 composição farmacêutica estável compreendendo um sal de vinflunina hidrossolúvel
CA2695039A CA2695039A1 (fr) 2007-07-11 2008-07-09 Composition pharmaceutique stable comprenant un sel de vinflunine hydrosoluble
PCT/EP2008/058893 WO2009007388A1 (fr) 2007-07-11 2008-07-09 Composition pharmaceutique stable comprenant un sel de vinflunine hydrosoluble
ARP080102967A AR067499A1 (es) 2007-07-11 2008-07-10 Composicion farmaceutica estable que comprende una sal de vinflunina hidrosoluble
TNP2010000013A TN2010000013A1 (en) 2007-07-11 2010-01-08 Stable pharmaceutical composition comprising a hydrosoluble vinflunine salt
ZA201000335A ZA201000335B (en) 2007-07-11 2010-01-18 Stable pharmaceutical composition comprising a hydrosoluble vinflunine salt
MA32552A MA32045B1 (fr) 2007-07-11 2010-01-25 Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine
CO10011475A CO6160316A2 (es) 2007-07-11 2010-02-03 Composicion farmaceutica estable que comprende una sal de vinflunina hidrosoluble
CL2008002005A CL2008002005A1 (es) 2007-07-11 2011-11-10 Composicion faramceutica solida, estable para administracion oral, que comprende una sal de vinflunina hidrosoluble y al menos un diluyente definido y un lubricante; uso para tratar el cancer.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0756421A FR2918566B1 (fr) 2007-07-11 2007-07-11 Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.

Publications (2)

Publication Number Publication Date
FR2918566A1 FR2918566A1 (fr) 2009-01-16
FR2918566B1 true FR2918566B1 (fr) 2009-10-09

Family

ID=38868376

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0756421A Expired - Fee Related FR2918566B1 (fr) 2007-07-11 2007-07-11 Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.

Country Status (21)

Country Link
US (1) US9173842B2 (fr)
EP (1) EP2187886A1 (fr)
JP (1) JP2010533139A (fr)
KR (1) KR20100047230A (fr)
CN (1) CN101730533B (fr)
AR (1) AR067499A1 (fr)
AU (1) AU2008274223A1 (fr)
BR (1) BRPI0814216A2 (fr)
CA (1) CA2695039A1 (fr)
CL (1) CL2008002005A1 (fr)
CO (1) CO6160316A2 (fr)
FR (1) FR2918566B1 (fr)
MA (1) MA32045B1 (fr)
NZ (1) NZ583040A (fr)
PA (1) PA8789101A1 (fr)
RU (1) RU2462248C2 (fr)
SA (1) SA08290417B1 (fr)
TN (1) TN2010000013A1 (fr)
TW (1) TW200914018A (fr)
WO (1) WO2009007388A1 (fr)
ZA (1) ZA201000335B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135856A2 (fr) * 2011-04-01 2012-10-04 Spectrum Pharmaceuticals, Inc. Vinorelbine à très faible dose pour le traitement du cancer
WO2013145750A1 (fr) * 2012-03-29 2013-10-03 杏林製薬株式会社 Préparation pharmaceutique de capsule
CN108289890B (zh) 2015-12-02 2021-04-27 日本新药株式会社 含有2-{4-[n-(5,6-二苯基吡嗪-2-基)-n-异丙基氨基]丁氧基}-n-(甲磺酰基)乙酰胺的医药组合物
CN106994121B (zh) * 2016-01-26 2021-07-02 江苏恒瑞医药股份有限公司 一种用于治疗癌症的药物组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558053A (en) 1983-12-21 1985-12-10 Eli Lilly And Company Naphthalene-1,5-disulfonate salts of dimeric indole-dihydroindole alkaloids
US5369094A (en) * 1990-11-29 1994-11-29 The Administrators Of The Tulane Educational Fund Polypeptide bombesin antagonists
FR2707988B1 (fr) * 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
FR2759293B1 (fr) * 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
FR2761990B1 (fr) * 1997-04-10 1999-06-25 Pf Medicament Derives halogenes antimitotiques d'alcaloides de vinca
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
AU2002213119A1 (en) 2000-10-13 2002-04-22 Bristol-Myers Squibb Company Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and vinorelbine and method of using the same
US6890558B2 (en) * 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
EP1530459B1 (fr) 2002-05-31 2010-03-31 R.P. Scherer Technologies, LLC Composition pharmaceutique orale pour capsules souples contenant de la vinorelbine et procede de traitement correspondant
US20070232533A1 (en) * 2003-05-09 2007-10-04 Kazuo Umezawa Use of Vinca Alkaloids and Salts Thereof
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation
CZ2004964A3 (cs) 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
WO2006040779A2 (fr) 2004-10-11 2006-04-20 Natco Pharma Limited Formule à matrice flottante gastrique à libération contrôlée contenant la substance imatinib
BRPI0519466B8 (pt) * 2004-12-30 2021-05-25 Pf Medicament dispersão sólida estável de um derivado de alcalóide de vinca e processo para a fabricação do mesmo
FR2880274B1 (fr) 2004-12-30 2007-04-13 Pierre Fabre Medicament Sa Dispersion solide stable d'un derive d'alcaloides de vinca et son procede de fabrication
FR2894966B1 (fr) * 2005-12-20 2008-03-14 Pierre Fabre Medicament Sa Nouvelle forme cristalline de la vinflunine
WO2009105937A1 (fr) 2008-02-29 2009-09-03 江苏豪森药业股份有限公司 Gélule molle de vinorelbine, son procédé de préparation et son application.

Also Published As

Publication number Publication date
AU2008274223A1 (en) 2009-01-15
SA08290417B1 (ar) 2013-01-22
RU2010103934A (ru) 2011-08-20
RU2462248C2 (ru) 2012-09-27
MA32045B1 (fr) 2011-02-01
CA2695039A1 (fr) 2009-01-15
PA8789101A1 (es) 2009-04-23
JP2010533139A (ja) 2010-10-21
CN101730533B (zh) 2013-05-29
US9173842B2 (en) 2015-11-03
BRPI0814216A2 (pt) 2015-10-27
CL2008002005A1 (es) 2009-06-26
CN101730533A (zh) 2010-06-09
WO2009007388A1 (fr) 2009-01-15
CO6160316A2 (es) 2010-05-20
EP2187886A1 (fr) 2010-05-26
TW200914018A (en) 2009-04-01
TN2010000013A1 (en) 2011-09-26
US20100196468A1 (en) 2010-08-05
FR2918566A1 (fr) 2009-01-16
ZA201000335B (en) 2010-10-27
KR20100047230A (ko) 2010-05-07
NZ583040A (en) 2012-03-30
AR067499A1 (es) 2009-10-14

Similar Documents

Publication Publication Date Title
BRPI0810646A2 (pt) " compostos farmacêuticos ".
HUE036378T2 (hu) Humán embrionális õssejtek felhasználási módszerei a gyógyászatban alkalmazott vegyületek és egyéb vegyszerek toxicitásának értékelésére
BRPI0912326A2 (pt) análogos de acetaminofeno hidrossolúveis
EP1862183A4 (fr) Composition pharmaceutique contenant un médicament à peine soluble dans l'eau
FR2903003B1 (fr) Utilisation d'un derive c-glycoside pour ameliorer la fonction barriere de la peau
FR2921143B1 (fr) Bague d'etancheite
FR2907311B3 (fr) Installation d'aquaculture pour micro-algues
FR2918566B1 (fr) Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
BRPI0820389A2 (pt) Formulação granulada usando um agente sequestrador de água
FR2906037B1 (fr) Detecteur d'eau
IL177981A0 (en) Rotary water sprinkler
GB2438311B (en) Water velocity corrections
FR2918567B1 (fr) Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
FR2935165B1 (fr) Bague d'etancheite
FR2889407B1 (fr) Pot d'exterieur pour plantes
FR2881026B1 (fr) Pot pour plantes
FR2957341B1 (fr) Produit solide compacte bicouche de purification d'eau
BRPI0821830A2 (pt) Composição líquida autoemulsionável de florfenicol destinada a ser incorporada à água de bebida dos animais de criação
FR2951966B1 (fr) Dispositif de mur d'eau modulaire
FR2922465B1 (fr) Epurateur d'eau
FR2897520B3 (fr) Ustensile d'assujettissement d'objets
TH85102B (th) ตู้จ่ายน้ำ
TH89740B (th) ปั๊มน้ำ
FR2890561B1 (fr) Composition ophtalmique contenant un sel de cysteamine
TH91313B (th) ก๊อกน้ำ

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

ST Notification of lapse

Effective date: 20200306